Physical and Social Factors Multiply Brain Ageing Risk Up to 9-Fold, Global Study Reveals

IMT News Desk
IMT News Desk
· 2 min read
A landmark Nature Medicine study across 34 countries reveals that combined physical and social environmental factors can accelerate brain ageing up to nine‑fold, with pollution, inequality, lack of green space, and poor healthcare access acting in a “syndemic” pattern. The analysis of 18,701 individuals calls for urgent, integrated policy action on urban planning, environmental justice, and dementia prevention.

A landmark international study across 34 countries warns that combined physical and social environmental factors can accelerate brain ageing by up to nine times, urging urgent policy action on pollution, inequality, and urban planning. Published in Nature Medicine, the research analyzed data from 18,701 individuals, revealing how everyday exposures like air pollution, lack of green spaces, poverty, and social inequality interact in a “syndemic” manner to hasten neurological decline.

Key Study Findings

Researchers quantified 73 environmental indicators, finding that joint physical exposures such as pollution, extreme temperatures, and scarce greenery drive structural brain ageing in memory and emotion-regulating regions via inflammation and vascular damage. Social factors like inequality and poor healthcare access amplify functional ageing in areas of cognition and social behavior, often surpassing dementia’s impact due to chronic stress. Together, these explained 15 times more variance in brain age than single factors, with effects consistent across healthy people and those with neurodegeneration.

Implications for Brain Health

The study highlights nonlinear risks: pollution paired with poverty multiplies damage far beyond isolated effects, especially in underserved regions. Protective elements like socioeconomic equality and green access slowed ageing, suggesting scalable interventions could preserve brain function. Experts call for holistic policies integrating environmental justice with dementia prevention.

Read Next

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet
News
April 16, 2026

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet

India’s stroke crisis demands urgent action, and the Indian Stroke Association (ISA) is leading the charge with a bold proposal for a unified national helpline. The ISA presented a comprehensive plan to strengthen stroke care delivery at a FICCI-hosted meeting attended by policymakers, healthcare leaders, and clinical experts. The plenary session, “Strengthening Stroke Care Delivery,” […]
Article by: IMT News Desk
Ivory raises fresh capital to strengthen deep tech offerings
News
April 16, 2026

Ivory raises fresh capital to strengthen deep tech offerings

Ivory, a brain health platform focused on early cognitive screening, has raised $1M in fresh funding, onboarding new investors to deepen its product, clinical and IP capabilities. The round saw participation from Draper Associates, a global venture capital firm with a strong focus on biotech and healthtech, along with SAGE Venture Fund, an AIF fund launched […]
Article by: IMT News Desk
Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition
News
April 16, 2026

Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition

Rubicon Research Limited today announced the acquisition of an 85% equity ownership in Arinna Lifesciences Limited from its current shareholders. With a portfolio of over 60 brands in chronic therapies, Arinna is one of the few domestic formulation companies principally focused on drugs treating conditions of the central nervous system (“CNS”) with more than 4,000 […]
Article by: IMT News Desk
MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide
News
April 16, 2026

MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide

MSN Laboratories has launched SEMABEST, its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO). SEMABEST is priced at nearly 50% lower than the innovator drug, significantly improving affordability and patient access. The therapy is available as a pre-filled pen for subcutaneous administration. In this evolving landscape, SEMABEST […]
Article by: IMT News Desk